What is the Senores Pharmaceuticals PE ratio today?
Senores Pharmaceuticals' PE ratio is 40.5 at the 29 October 2026 close (₹1,219.20 a share): a market capitalisation of ₹5,614 crore divided by consolidated net profit attributable to shareholders of ₹139 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹122 crore) it is 46.2.
What is the Senores Pharmaceuticals PB ratio (price to book value)?
Senores Pharmaceuticals' price-to-book (PB) ratio is 5.60 at the 29 October 2026 close: a market capitalisation of ₹5,614 crore divided by shareholders' equity (book value) of ₹1,003 crore on 30 September 2026. That is a book value of ₹217.80 per share against a share price of ₹1,219.20.
What is the Senores Pharmaceuticals ROE and ROCE?
In FY26, Senores Pharmaceuticals' return on equity (ROE) was 14.1% and its return on capital employed (ROCE) was 12.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the Senores Pharmaceuticals market cap?
Senores Pharmaceuticals' market capitalisation was ₹5,614 crore at the 29 October 2026 close: 4.61 crore shares at ₹1,219.20 each.
Is Senores Pharmaceuticals debt free?
No. Senores Pharmaceuticals had borrowings of ₹394 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.38. Its cash and current investments were ₹101 crore, so its net debt was ₹294 crore.
What is the Senores Pharmaceuticals EPS?
Senores Pharmaceuticals' basic earnings per share (EPS) were ₹26.39 in FY26, against ₹16.12 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹30.71.
What is the Senores Pharmaceuticals debt to equity ratio?
Senores Pharmaceuticals' debt-to-equity ratio was 0.38 on 30 September 2026: borrowings of ₹394 crore against total equity of ₹1,032 crore. A year earlier, on 30 September 2025, it was 0.28.
What is the Senores Pharmaceuticals promoter holding?
Promoters held 45.82% of Senores Pharmaceuticals on 30 September 2026, unchanged from the previous quarter and up 0.02 percentage points from 45.80% a year earlier, according to the shareholding pattern filed with NSE.
What is the Senores Pharmaceuticals revenue and profit in FY26?
In FY26 (April 2025–March 2026), Senores Pharmaceuticals' consolidated net profit attributable to shareholders was ₹122 crore, up 108.3% from ₹58.3 crore in FY25, on revenue from operations of ₹633 crore (up 58.9%).
What is the Senores Pharmaceuticals net worth?
Senores Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,003 crore on 30 September 2026, up 23.2% from ₹814 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹5,614 crore at the 29 October 2026 close.
What is the Senores Pharmaceuticals book value per share?
Senores Pharmaceuticals' book value per share was ₹217.80 on 30 September 2026: shareholders' equity of ₹1,003 crore divided by the 4.61 crore shares in issue, up 23.2% from ₹176.77 a year earlier. The share price at the 29 October 2026 close was ₹1,219.20.
What is the Senores Pharmaceuticals free cash flow?
In FY26, Senores Pharmaceuticals generated ₹62.1 crore of cash from operations and spent ₹240 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹178 crore. In FY25 it was −₹203 crore.
What is the Senores Pharmaceuticals shareholding pattern?
On 30 September 2026, Senores Pharmaceuticals' shares were held by promoters 45.82%, foreign portfolio investors (FII/FPI) 6.01%, domestic institutions (DII) 10.84% (including mutual funds at 7.36%) and retail and other non-institutional investors 37.33%. Over the year, FII holding was up 1.73 percentage points from 4.28% and DII holding was up 2.23 percentage points from 8.61%.
How does Senores Pharmaceuticals compare with its peers?
On FY26 consolidated figures, against Innova Captab and Morepen Laboratories: Senores Pharmaceuticals' operating margin of 21.7% is the highest of the three (Innova Captab 12.1%, Morepen Laboratories 4.9%; peer average 8.5%); its return on equity of 14.1% is the highest of the three (Innova Captab 14.0%, Morepen Laboratories 7.9%; peer average 11.0%).
How does the Senores Pharmaceuticals PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Senores Pharmaceuticals' PE ratio is 46.2, the second highest of the three: Innova Captab 42.0 and Morepen Laboratories 68.9, a peer average of 55.5. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What are the Senores Pharmaceuticals latest quarterly results?
Senores Pharmaceuticals' latest results are for Q2 FY27 (July–September 2026): consolidated net profit attributable to shareholders ₹39.5 crore, up 22.0% from ₹32.4 crore in Q2 FY26; revenue from operations ₹192 crore, up 18.9% year on year.
When are the Senores Pharmaceuticals next results?
Senores Pharmaceuticals has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Senores Pharmaceuticals vs Innova Captab: how do they compare?
In FY26, Senores Pharmaceuticals earned net profit attributable to shareholders of ₹122 crore on revenue of ₹633 crore, against ₹143 crore on ₹1,630 crore for Innova Captab. Senores Pharmaceuticals' operating margin was 21.7% (Innova Captab 12.1%) and its return on equity 14.1% (Innova Captab 14.0%). At the 29 October 2026 close, Senores Pharmaceuticals' market capitalisation was ₹5,614 crore against ₹6,015 crore for Innova Captab, and its PE ratio on FY26 profit 46.2 against 42.0.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
